Pamela Salman

14.8k total citations · 2 hit papers
22 papers, 3.4k citations indexed

About

Pamela Salman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pamela Salman has authored 22 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Pamela Salman's work include Gastric Cancer Management and Outcomes (10 papers), Renal cell carcinoma treatment (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Pamela Salman is often cited by papers focused on Gastric Cancer Management and Outcomes (10 papers), Renal cell carcinoma treatment (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Pamela Salman collaborates with scholars based in Chile, United States and Brazil. Pamela Salman's co-authors include Carlos H. Barrios, Oleg Gladkov, Cezary Szczylik, Lauren McCann, Jozef Mardiak, Eunsik Lee, Ian D. Davis, Robert E. Hawkins, John Wagstaff and Cora N. Sternberg and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Pamela Salman

20 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

2010 1.9k citations Cora N. Sternberg, Ian D. Davis et al. Journal of Clinical Oncology profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Pamela Salman

Since Specialization

Citations

This map shows the geographic impact of Pamela Salman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Salman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Salman more than expected).

Fields of papers citing papers by Pamela Salman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Salman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Salman. The network helps show where Pamela Salman may publish in the future.

Co-authorship network of co-authors of Pamela Salman

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Salman. A scholar is included among the top collaborators of Pamela Salman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Salman. Pamela Salman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unraveling the complex link between vitamin D levels and cancer: A crucial understanding for designing future supplementation approaches 2023 ·Brazilian Journal of Pharmaceutical Sciences ·Pamela Salman, (unknown), Cristian Soza‐Ried	1
2	Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial 2023 ·Journal of Clinical Oncology ·Cora N. Sternberg, (unknown), Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg Gladkov, Alexander Kavina, (unknown), (unknown), Lauren McCann, Lini Pandite, Debasish Roychowdhury, Robert E. Hawkins	10
3	Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries 2021 ·JCO Global Oncology ·(unknown), (unknown), Aldo Lourenço Abbade Dettino, (unknown), (unknown), Ariel Galapo Kann, Carlos Dzik, Daniel Herchenhorn, Denis L. Jardim, (unknown), Mouna Ayadi, Pamela Salman, Ray Manneh Kopp, (unknown), (unknown), (unknown), (unknown), Pedro Luiz Serrano Usón, Andrey Soares	1
4	Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety 2021 ·ecancermedicalscience ·Luis J. Villanueva-Rivera, (unknown), Jean M. Butte, Pamela Salman, (unknown), (unknown), Carlos Gallardo, (unknown), (unknown), (unknown), Olga Barajas, Luis Matamala, (unknown), (unknown), (unknown), Christian Caglevic, (unknown)	10
5	First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. 2021 ·Journal of Clinical Oncology ·Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, (unknown), Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Mingshun Li, Dana Cullen, Arteid Memaj, Ming Lei, Hong Xiao, Yelena Y. Janjigian, Jaffer A. Ajani	12
6	LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study 2020 ·Annals of Oncology ·Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, (unknown), Michael Schenker, Patricio Yañez, Mustapha Tehfé, Valerie Poulart, Dana Cullen, Ming Lei, Kaoru Kondo, (unknown), Jaffer A. Ajani, Yelena Y. Janjigian	139
7	Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America 2019 ·Advances in Therapy ·David Queiroz Borges Muniz, (unknown), Hongbo Yang, (unknown), (unknown), James Signorovitch, Luca Dezzani, Pamela Salman, Mauricio Lema, (unknown), Guillermo Lerzo, (unknown), Matías Chacón, (unknown), Saúl Campos-Gómez	2
8	Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer 2018 ·OncoTargets and Therapy ·Pamela Salman, (unknown), (unknown), Mauricio Mahave, Cristian Soza‐Ried	9
9	Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC). 2018 ·Journal of Clinical Oncology ·Luis J. Villanueva-Rivera, (unknown), Olga Barajas, Carlos Gallardo, José Luis Leal, Mauricio Mahave, Luis Matamala, (unknown), (unknown), Pamela Salman, Jean M. Butte, (unknown), Nicolás Devaud, (unknown), (unknown), (unknown), (unknown), Christian Caglevic	0
10	CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups 2017 ·Annals of Oncology ·Bernard Escudier, Nizar M. Tannir, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Elizabeth R. Plimack, Philippe Barthélémy, Saby George, Victoria Neiman, Camillo Porta, Toni K. Choueiri, Thomas Powles, Frede Donskov, Pamela Salman, Christian Kollmannsberger, Brian I. Rini, Sabeen Mekan, M. Brent McHenry, Hans J. Hammers, Robert J. Motzer	68
11	Global Cancer Institute multidisciplinary tumor boards as a tool to improve patterns of clinical practice for breast and gynecologic cancer in resource-limited settings. 2017 ·Journal of Clinical Oncology ·Jessica St. Louis, Alexandra Bukowski, (unknown), (unknown), (unknown), André Lopes, (unknown), (unknown), (unknown), Cynthia Villarreal‐Garza, (unknown), (unknown), Pamela Salman, (unknown), Paul E. Goss	2
12	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). 2016 ·Journal of Clinical Oncology ·Bernard Escudier, Robert J. Motzer, Thomas Powles, Nizar M. Tannir, Ian D. Davis, Frede Donskov, Viktor Grünwald, Daniel Yick Chin Heng, (unknown), Bohuslav Melichar, (unknown), Brian I. Rini, Pamela Salman, Cora N. Sternberg, Cezary Szczylik, Pascal Wolter, (unknown), Milan Mangeshkar, Neeraj Agarwal, Toni K. Choueiri	8
13	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx). 2015 ·Journal of Clinical Oncology ·Yung‐Jue Bang, Shukui Qin, (unknown), Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Marc Buyse, Karen Afenjar, Vincent Houé, (unknown), Yingjie Huang, Alison Armour, Dennis J. Slamon, J. Randolph Hecht	1
14	A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update 2013 ·European Journal of Cancer ·Cora N. Sternberg, Robert E. Hawkins, John Wagstaff, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Juan José Zarbá, Oleg Gladkov, Eunsik Lee, Cezary Szczylik, Lauren McCann, Stephen D. Rubin, Mei Chen, Ian D. Davis	349
15	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial breakdown → 2013 ·The Lancet Oncology ·Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung, Pamela Salman, Sang Cheul Oh, G. Bodoky, G. Kurteva, Constantin Volovăț, Vladimir Moiseyenko, В. А. Горбунова, Joon Oh Park, Akira Sawaki, Ilhan Celik, Heiko Götte, Helena Melezínková, Markus Moehler	621
16	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. 2013 ·Journal of Clinical Oncology ·J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, (unknown), Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Marc Buyse, Karen Afenjar, Tomomi Kaneko, (unknown), Sergio Santillana, Michael F. Press, Dennis J. Slamon	97
17	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial. 2013 ·Journal of Clinical Oncology ·J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, (unknown), Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Marc Buyse, Karen Afenjar, Tomomi Kaneko, (unknown), Sergio Santillana, Michael F. Press, Dennis J. Slamon	5
18	Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study 2012 ·Annals of Oncology ·Florian Lordick, G. Bodoky, (unknown), G. Kurteva, Yoon‐Koo Kang, (unknown), Pamela Salman, (unknown), Helena Melezínková, Markus Moehler	9
19	Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial breakdown → 2010 ·Journal of Clinical Oncology ·Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg Gladkov, Alexander Kavina, Juan José Zarbá, Chen Mei, Lauren McCann, Lini Pandite, Debasish Roychowdhury, Robert E. Hawkins	1940
20	Diagnosis of Pneumonia and Monitoring of Infection Eradication 2000 ·Drugs ·Mauricio Ruiz, Cristina Arosio, Pamela Salman, Torsten Bauer, Antoni Torres	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact